Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,061 JPY | -0.68% | -2.07% | +0.15% |
Apr. 18 | Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease | DJ |
Apr. 16 | Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds | MT |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited